Evidence map›Paper›PMID 38050082›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2024

Polypathologic Associations with Gray Matter Atrophy in Neurodegenerative Disease.

Jeffrey S Phillips, John L Robinson, Katheryn A Q Cousins, David A Wolk, Edward B Lee, Corey T McMillan, John Q Trojanowski, Murray Grossman, David J Irwin

Open access · greenAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jeffrey S PhillipsDepartments of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 jeffrey.phillips@pennmedicine.upenn.edu.
John L RobinsonPathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Katheryn A Q CousinsDepartments of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
David A WolkDepartments of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Edward B LeePathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Corey T McMillanDepartments of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
John Q TrojanowskiPathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Murray GrossmanDepartments of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104.ORCID 0000-0002-7447-6218
David J IrwinDepartments of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
University of Pennsylvania · US

Funding

Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Corey T McMillan · 2021 to 2026
$24.8M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Lauren M Massimo · 2020 to 2026
$18.8M
Project IV: In Vivo Dissection of Genetic Modifiers on Different Stages of SynucleinopathyP01AG084497 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Kelvin C Luk · 2024 to 2026
$15.2M
Spreading Tau Pathology in Non-Amnestic Alzheimer's DiseaseR01AG054519 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jeffrey S Phillips · 2018 to 2026
$7.4M
Multidimensional Approaches to Understanding Consequences and Mechanisms of Apathy in Frontotemporal DegenerationR01AG076832 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Lauren M Massimo · 2022 to 2026
$2.6M
A Network Neuroscience Investigation of Disease Spread in Non-Amnestic Mild Cognitive ImpairmentK01AG061277 · NIA · UNIVERSITY OF PENNSYLVANIA · PI PHILLIPS, JEFFREY S · 2019 to 2023
$583k
NIA NIH HHS K01 AG061277NIA NIH HHS P01 AG066597NIA NIH HHS P01 AG084497NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG054519NIA NIH HHS R01 AG076832
6 · The paper itself

Abstract

Mixed pathologies are common in neurodegenerative disease; however, antemortem imaging rarely captures copathologic effects on brain atrophy due to a lack of validated biomarkers for non-Alzheimer's pathologies. We leveraged a dataset comprising antemortem MRI and postmortem histopathology to assess polypathologic associations with atrophy in a clinically heterogeneous sample of 125 human dementia patients (41 female, 84 male) with T1-weighted MRI ≤ 5 years before death and postmortem ordinal ratings of amyloid-[Formula: see text], tau, TDP-43, and [Formula: see text]-synuclein. Regional volumes were related to pathology using linear mixed-effects models; approximately 25% of data were held out for testing. We contrasted a polypathologic model comprising independent factors for each proteinopathy with two alternatives: a model that attributed atrophy entirely to the protein(s) associated with the patient's primary diagnosis and a protein-agnostic model based on the sum of ordinal scores for all pathology types. Model fits were evaluated using log-likelihood and correlations between observed and fitted volume scores. Additionally, we performed exploratory analyses relating atrophy to gliosis, neuronal loss, and angiopathy. The polypathologic model provided superior fits in the training and testing datasets. Tau, TDP-43, and [Formula: see text]-synuclein burden were inversely associated with regional volumes, but amyloid-[Formula: see text] was not. Gliosis and neuronal loss explained residual variance in and mediated the effects of tau, TDP-43, and [Formula: see text]-synuclein on atrophy. Regional brain atrophy reflects not only the primary molecular pathology but also co-occurring proteinopathies; inflammatory immune responses may independently contribute to degeneration. Our findings underscore the importance of antemortem biomarkers for detecting mixed pathology.

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesAmyloidAtrophyBiomarkersDNA-Binding ProteinsFemaleGliosisGray MatterHumansMaleSynucleinstau ProteinsAmyloidBiomarkersDNA-Binding ProteinsSynucleinstau Proteinsamyloid-βatrophycopathologytauTDP-43α-synuclein

Identifiers

PMID38050082
PMCPMC10860605
OpenAlexW4388894268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.